Amundi raised its holdings in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 28.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 670,350 shares of the biopharmaceutical company’s stock after buying an additional 150,431 shares during the quarter. Amundi owned about 0.35% of Incyte worth $49,023,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Andra AP fonden increased its position in shares of Incyte by 7.9% during the fourth quarter. Andra AP fonden now owns 212,500 shares of the biopharmaceutical company’s stock valued at $14,677,000 after purchasing an additional 15,500 shares during the period. Edgestream Partners L.P. increased its position in shares of Incyte by 173.0% during the fourth quarter. Edgestream Partners L.P. now owns 61,174 shares of the biopharmaceutical company’s stock valued at $4,225,000 after purchasing an additional 38,766 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in shares of Incyte during the fourth quarter valued at approximately $717,000. Candriam S.C.A. increased its position in shares of Incyte by 27.8% during the fourth quarter. Candriam S.C.A. now owns 1,034,652 shares of the biopharmaceutical company’s stock valued at $71,463,000 after purchasing an additional 224,919 shares during the period. Finally, Inceptionr LLC bought a new stake in shares of Incyte during the fourth quarter valued at approximately $844,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Incyte
In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total value of $1,042,090.83. Following the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,914,561.36. This represents a 35.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the sale, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This trade represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,320 shares of company stock valued at $2,072,849. 17.60% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on Incyte
Incyte Trading Down 0.5 %
NASDAQ:INCY opened at $67.73 on Thursday. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The business’s 50-day moving average price is $71.82 and its two-hundred day moving average price is $70.27. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $13.11 billion, a price-to-earnings ratio of 250.86, a PEG ratio of 0.41 and a beta of 0.76.
Incyte (NASDAQ:INCY – Get Free Report) last released its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities analysts expect that Incyte Co. will post 4.86 earnings per share for the current year.
Incyte Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Read More
- Five stocks we like better than Incyte
- Expert Stock Trading Psychology Tips
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Basic Materials Stocks Investing
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.